Faculty of Health Sciences
School of Medicine
Department of Medical Oncology
Research articles in refereed specialist journals
Biganzoli L, Cufer T, Bruning P, Coleman RE, Duchateau L, Rapoport BL, Nooij M, Delhaye F, Miles D, Sulkes A, Hamilton A, Piccart M: 2003. Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial. Cancer, 97 (1) / Jan, pp 40-45.
Kornblith AB, Herndon JE, Weiss RB, Zhang C, Zuckerman EL, Rosenberg S, Mertz MS, Payne D, Massie MJ, Holland JF, Wingate P, Norton L, Holland JC: 2003. Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy. Cancer, 98 (4) / Aug, pp 679-689.
Vorobiof DA, Rapoport BL, Chasen MR, Cohen GL, Mahomed R, Karime M: 2003. Phase II clinical trial of carboplatin and docetaxel in patients with metastataic ovarian cancer: Active combination with low incidence of peripheral neuropathy. International Journal of Gynecological Cancer, 13 (3) / May/Jun, pp 287-291.
Weiss RB, Woolf SH, Demakos E, Holland JF, Berry DA, Falkson G, Cirrincione CT, Robbins A, Bothun S, Henderson IC, Norton L: 2003. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. Journal of Clinical Oncology, 21 (9) / May, pp 1825-1835.
Nabholtz JM, Falkson CI, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof DA, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P: 2003. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. Journal of Clinical Oncology, 21 (6) / Mar, pp 968-975.
de Wit R, Herrstedt J, Rapoport BL, Carides AD, Carides G, Elmer M, Schmidt C, Evans JK, Horgan KJ: 2003. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. Journal of Clinical Oncology, 21 (22) / Nov, pp 4105-4111.
Vorobiof DA, Rapoport BL, Mahomed R, Karime M: 2003. Phase II study of pegylated liposomal doxorubicin in patients with metastatic malignant melanoma failing standard chemotherapy treatment. Melanoma Research, 13 (2) / April, pp 201-203.
Abratt RP, Eele R, Goedhals L, Rapoport BL, Slabber CF, Vorobiof DA: 2003. Guidelines for CPD Accreditation of the South African Society of Medical Oncology. South African Medical Journal, 93 (10) / Oct, p. 728.
|
